|
US10865245B2
(en)
|
2014-12-23 |
2020-12-15 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
WO2016106004A1
(en)
|
2014-12-23 |
2016-06-30 |
Full Spectrum Genetics, Inc. |
Novel anti-b7h3 binding compounds and uses thereof
|
|
WO2016207104A1
(de)
*
|
2015-06-23 |
2016-12-29 |
Bayer Pharma Aktiengesellschaft |
Antikörper-wirkstoff-konjugate (adcs) von ksp-inhibitoren mit anti-b7h3-antikörpern
|
|
US12128102B2
(en)
|
2016-03-08 |
2024-10-29 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CA3026588A1
(en)
*
|
2016-07-01 |
2018-01-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitory immune receptor inhibition methods and compositions
|
|
CA3050085A1
(en)
|
2017-01-20 |
2018-07-26 |
Juno Therapeutics Gmbh |
Cell surface conjugates and related cell compositions and methods
|
|
CN109843927B
(zh)
*
|
2017-03-06 |
2022-06-21 |
江苏恒瑞医药股份有限公司 |
抗b7-h3抗体、其抗原结合片段及其医药用途
|
|
BR112019019111A2
(pt)
|
2017-03-31 |
2020-05-05 |
Jiangsu Hengrui Medicine Co., Ltd. |
anticorpo de b7-h3, seu fragmento de ligação ao antígeno e seu uso médico
|
|
SG11201909160WA
(en)
|
2017-04-11 |
2019-10-30 |
Inhibrx Inc |
Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
|
|
CN110799542A
(zh)
*
|
2017-05-12 |
2020-02-14 |
纪念斯隆-凯特琳癌症中心 |
抗-b7h3抗体用于治疗中枢神经系统癌症的用途
|
|
CN109963591B
(zh)
*
|
2017-08-04 |
2023-04-04 |
江苏恒瑞医药股份有限公司 |
B7h3抗体-药物偶联物及其医药用途
|
|
KR102776166B1
(ko)
|
2017-08-07 |
2025-03-04 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
안전한 세포 치료제를 생성하기 위한 플랫폼
|
|
CA3073227A1
(en)
|
2017-08-17 |
2019-02-21 |
Michael D. Miller |
Firearm assembly system and method
|
|
IL273119B2
(en)
|
2017-09-08 |
2023-10-01 |
Maverick Therapeutics Inc |
Binding proteins are activated under limited conditions
|
|
EP3700938A1
(en)
*
|
2017-10-26 |
2020-09-02 |
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. |
Novel recombinant fusion proteins, preparation and use thereof
|
|
CA3080835A1
(en)
|
2017-10-31 |
2019-05-09 |
Pantarhei Bioscience B.V. |
Immunotherapeutic methods for treating and/or preventing lung cancer
|
|
CN109939126A
(zh)
*
|
2017-12-21 |
2019-06-28 |
张曼 |
Cd3×b7h3双特异抗体定向杀伤耐阿霉素膀胱癌细胞pumc-91/adm的应用
|
|
CN109939231A
(zh)
*
|
2017-12-21 |
2019-06-28 |
张曼 |
关于cd3×b7h3双特异性抗体定向杀伤膀胱癌细胞t24的应用
|
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
|
BR112020014399A2
(pt)
*
|
2018-01-15 |
2020-12-29 |
Stichting Sanquin Bloedvoorziening |
Anticorpos potenciadores do fator h e seus usos
|
|
WO2019200022A1
(en)
|
2018-04-11 |
2019-10-17 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
|
|
WO2019225787A1
(ko)
*
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
|
KR20210035805A
(ko)
|
2018-06-15 |
2021-04-01 |
플래그쉽 파이어니어링 이노베이션스 브이, 인크. |
세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
|
|
WO2020018964A1
(en)
|
2018-07-20 |
2020-01-23 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for controlled expression of antigen-specific receptors
|
|
TW202035451A
(zh)
|
2018-07-24 |
2020-10-01 |
美商英伊布里克斯公司 |
含有受限cd3結合域及受體結合區之多重特異性多肽構築體及其使用方法
|
|
WO2020041626A1
(en)
*
|
2018-08-23 |
2020-02-27 |
The Board Of Trustees Of The Leland Stanford Junior University |
Affibody proteins specific for b7-h3 (cd276)
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CA3115082A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
B7h3 single domain antibodies and therapeutic compositions thereof
|
|
CN112533955B
(zh)
*
|
2018-11-22 |
2023-06-09 |
苏州鑫康合生物医药科技有限公司 |
抗b7-h3抗体
|
|
EP4592313A3
(en)
|
2019-03-05 |
2025-11-19 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
|
CN109929039A
(zh)
*
|
2019-03-28 |
2019-06-25 |
郑州大学第一附属医院 |
基于cd276抗体的嵌合抗原受体、慢病毒表达载体及其应用
|
|
EP3962493A2
(en)
|
2019-05-03 |
2022-03-09 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
|
|
IL288024B2
(en)
|
2019-05-14 |
2025-12-01 |
Provention Bio Inc |
Methods and compositions for preventing type
|
|
WO2020238926A1
(en)
*
|
2019-05-28 |
2020-12-03 |
Single Cell Technology, Inc. |
Anti-b7-h3 antibodies
|
|
CN114173813A
(zh)
|
2019-07-03 |
2022-03-11 |
晶体生物科学股份有限公司 |
抗b7-h3抗体及其使用方法
|
|
KR102732027B1
(ko)
*
|
2019-07-09 |
2024-11-20 |
주식회사 와이바이오로직스 |
B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
|
|
BR112022000739A2
(pt)
|
2019-07-17 |
2022-04-12 |
Gemini Therapeutics Sub Inc |
Anticorpos de potencialização de fator h e usos dos mesmos
|
|
EP4022313A1
(en)
|
2019-08-30 |
2022-07-06 |
Y-Mabs Therapeutics, Inc. |
Immunohistochemical assessment of b7-h3 expression
|
|
CN110642948B
(zh)
*
|
2019-10-09 |
2021-06-29 |
达石药业(广东)有限公司 |
B7-h3纳米抗体、其制备方法及用途
|
|
AU2020387401A1
(en)
*
|
2019-11-18 |
2022-05-26 |
Board Of Regents, The University Of Texas System |
Anti-B7-H3 monoclonal antibody and methods of use thereof
|
|
EP4076434A1
(en)
|
2019-12-17 |
2022-10-26 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
|
KR20220148175A
(ko)
|
2020-01-29 |
2022-11-04 |
인히브릭스, 인크. |
Ｃｄ28 단일 도메인 항체 및 이의 다가 및 다중특이적 구조체
|
|
EP4138931A1
(en)
*
|
2020-04-24 |
2023-03-01 |
Y-Mabs Therapeutics, Inc. |
B7h3 antibodies with chelators
|
|
CA3178510A1
(en)
|
2020-06-04 |
2021-12-09 |
Ahmed Mahiuddin |
Anti-b7h3 antibodies for the treatment of cancer
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
US20230355804A1
(en)
|
2020-06-29 |
2023-11-09 |
Flagship Pioneering Innovations V, Inc. |
Viruses engineered to promote thanotransmission and their use in treating cancer
|
|
CN112961242B
(zh)
*
|
2020-06-30 |
2022-01-04 |
广州百暨基因科技有限公司 |
抗b7h3抗体及其应用
|
|
CN116635064A
(zh)
|
2020-12-18 |
2023-08-22 |
世纪治疗股份有限公司 |
具有适应性受体特异性的嵌合抗原受体系统
|
|
AU2021407023B2
(en)
*
|
2020-12-23 |
2025-12-04 |
Fortvita Biologics (Singapore) Pte.Ltd. |
Anti-b7-h3 antibody and uses thereof
|
|
KR20230145038A
(ko)
|
2021-02-09 |
2023-10-17 |
메디링크 테라퓨틱스 (쑤저우) 컴퍼니, 리미티드 |
생물활성 물질 접합체, 이의 제조방법 및 이의 용도
|
|
CA3214085A1
(en)
|
2021-03-31 |
2022-10-06 |
Darby Rye Schmidt |
Thanotransmission polypeptides and their use in treating cancer
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
EP4363059A1
(en)
|
2021-06-29 |
2024-05-08 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
WO2023041015A1
(en)
*
|
2021-09-18 |
2023-03-23 |
Skyline Therapeutics (Shanghai) Co., Ltd. |
Aav for the gene therapy of wet-amd
|
|
US20250230244A1
(en)
*
|
2021-10-05 |
2025-07-17 |
Board Of Regents, The University Of Texas System |
Methods and compositions comprising b7-h3 binding polypetides
|
|
WO2023134716A1
(zh)
*
|
2022-01-14 |
2023-07-20 |
盛禾(中国)生物制药有限公司 |
一种结合b7h3和nkp30的双特异性抗体及其应用
|
|
EP4480499A1
(en)
|
2022-02-16 |
2024-12-25 |
Medilink Therapeutics (Suzhou) Co., Ltd. |
Conjugate of antibody-eribulin or derivative thereof, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and use thereof
|
|
PE20251671A1
(es)
|
2022-03-15 |
2025-06-30 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
|
|
CN116836281A
(zh)
*
|
2022-03-25 |
2023-10-03 |
英诺湖医药(杭州)有限公司 |
B7h3抗体及包含其的双功能抗体
|
|
KR20250011957A
(ko)
*
|
2022-05-18 |
2025-01-22 |
우시 바이올로직스 아일랜드 리미티드 |
항-b7h3 항체 및 이의 용도
|
|
JP2025516873A
(ja)
|
2022-05-18 |
2025-05-30 |
▲蘇▼州宜▲聯▼生物医▲薬▼有限公司 |
タンパク質分解剤クラスの生物学的活性化合物を含む抗体薬物複合体及びその調製方法並びに使用
|
|
WO2024037627A1
(zh)
*
|
2022-08-19 |
2024-02-22 |
盛禾(中国)生物制药有限公司 |
一种双特异性抗体及其应用
|
|
EP4598946A1
(en)
|
2022-10-05 |
2025-08-13 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
CN115819608A
(zh)
*
|
2022-10-08 |
2023-03-21 |
盛禾(中国)生物制药有限公司 |
一种纯化融合蛋白的方法
|
|
CN115845047A
(zh)
*
|
2022-11-07 |
2023-03-28 |
盛禾(中国)生物制药有限公司 |
一种异源二聚体蛋白质组合物
|
|
WO2024106939A1
(ko)
*
|
2022-11-15 |
2024-05-23 |
주식회사 셀랩메드 |
B7-h3에 특이적으로 결합하는 항체
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
|
WO2025129565A1
(zh)
*
|
2023-12-21 |
2025-06-26 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种cd276迷你结合蛋白及其突变体及应用
|
|
WO2025245264A1
(en)
*
|
2024-05-21 |
2025-11-27 |
Briapro Therapeutics Corp. |
Anti-b7-h3 antibodies and methods of use thereof
|